NYXH Nyxoah

Information on the total number of voting rights and shares

Information on the total number of voting rights and shares

REGULATED INFORMATION

Information on the total number of voting rights and shares

Mont-Saint-Guibert (Belgium), November 20, 2025, 10:30 pm CET / 4:30 pm ET – In accordance with article  15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.

  • Share capital: EUR 6.504.688,76
  • Total number of securities carrying voting rights: 43,026,460 (all ordinary shares)
  • Total number of voting rights (= denominator): 43,026,460 (all relating to ordinary shares)
  • Number of rights to subscribe to securities carrying voting rights not yet issued: 3,258,819 (all granted subscription rights; this number excludes 692,677 subscription rights that were issued but not yet granted)

*

* *

Contact:

Nyxoah

John Landry, CFO

Attachment



EN
20/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE

Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity...

Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth Nyxoah Invests In Further Expanding Its Belgian Manufacturing Capacity To Support Its Worldwide Growth Mont-Saint-Guibert, Belgium – January 21, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced an important investment in Belgium to further scale its manufacturing capacity to suppo...

 PRESS RELEASE

Nyxoah Investit Dans l'Expansion De Sa Capacité De Production En Belgi...

Nyxoah Investit Dans l'Expansion De Sa Capacité De Production En Belgique Afin De Soutenir Sa Croissance Mondiale Nyxoah Investit Dans l'Expansion De Sa Capacité De Production En Belgique Afin De Soutenir Sa Croissance Mondiale Mont-Saint-Guibert, Belgique – 21 janvier 2026, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») une société de technologie médicale spécialisée dans le développement et la commercialisation de solutions innovantes pour le traitement de l'Apnée Obstructive du Sommeil (« AOS ») par neuromodulation, a annoncé aujourd'h...

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
 PRESS RELEASE

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Y...

Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 INSIDE INFORMATIONREGULATED INFORMATION Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 Strong Start in First Full Quarter of U.S. Commercialization Mont-Saint-Guibert, Belgium – January 12, 2026, 10:05 pm CET / 4:05 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment a...

 PRESS RELEASE

Nyxoah Annonce ses Résultats Préliminaires pour le Quatrième Trimestre...

Nyxoah Annonce ses Résultats Préliminaires pour le Quatrième Trimestre et l'Ensemble de l'Exercice 2025 et Communique des Prévisions de Chiffre d'Affaires pour le Premier Trimestre 2026 INFORMATIONS PRIVILÉGIÉESINFORMATIONS RÉGLEMENTÉES Nyxoah Annonce ses Résultats Préliminaires pour le Quatrième Trimestre et l'Ensemble de l'Exercice 2025 et Communique des Prévisions de Chiffre d'Affaires pour le Premier Trimestre 2026 Un Démarrage Solide pour le Premier Trimestre Complet de Commercialisation aux États-Unis Mont-Saint-Guibert, Belgique – 12 janvier 2026, 22h05 CET / 16h05 ET – Nyxoah SA ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch